Xeris and Beta Bionics today announced an exclusive worldwide collaboration to develop a glucagon product for proprietary pump technology.
The collaboration and license agreement covers the development and commercialization of a glucagon product utilizing the Xeris XeriSol technology. Xeris and Beta Bionics aim to utilize the product with proprietary bi-hormonal pump and pump systems.
Glucagon, a hormone that raises blood glucose levels, helps to treat severe hypoglycemia. Current administration forms for glucagon include a spray into the nose or an injection administered under the skin. The companies believe their collaboration could add another option for people with diabetes.
“If insulin is like the gas pedal in your car, then glucagon is the brakes. Beta Bionics has always felt that a bi-hormonal glucose control system has real advantages over insulin alone…just like the brakes in your car,” said Sean Saint, the company’s CEO. Now with this partnership with Xeris, we are ready to take the next step in bringing this system to market.”
Under the terms of the agreement, Xeris can receive development payments, plus low-double-digit royalties. These payments remain contingent on future sales of the Xeris glucagon for pumps and pump systems.
“We’re excited to be partnering with Beta Bionics by being the exclusive provider of the glucagon component that will facilitate their development of the first dual-hormone pump for people with diabetes,” said Paul R. Edick, chair and CEO of Xeris. “We will move quickly to support Beta Bionics in this important development program.”
